- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
U.S. FDA Approves Sanofi's Bleeding Disorder Therapy
The US FDA has approved Sanofi's therapy, Altuviiio, for hemophilia A, a type of inherited bleeding disorder. Altuviiio is expected to be launched in the US in April and is likely to be one of the best in its class, according to an analyst. The average annual cost of existing clotting factor therapies is approximately $300,000, and Sanofi will price Altuviiio at parity with the annual cost of treating a prophylaxis patient on Eloctate. Altuviiio is expected to compete with other factor replacement therapies, including those from Takeda Pharmaceutical, Bayer, and Novo Nordisk.
Transforming Cancer Care: Data, AI, and Patient-Centered Care
July 20th 2023Join us as Mohit Manrao, SVP and head of US oncology at AstraZeneca, shares his patient-centered approach to transforming cancer care, bridging the gap between innovative science and tangible patient outcomes across all populations on a global scale.
